Glenmark Pharmaceuticals S.A. is a R&D centre focused on biologics established in 2004. It is a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (India). The biologics research centre focuses on discovery and development of novel biological entities, comprising of monoclonal antibody products targeted towards oncology and inflammation disease areas. The unit has all capabilities required to develop antibody products and take them rapidly from early discovery to clinical phase testing.
Contact
Street: Chemin de la Combeta 5
ZIP: 2300
City: La Chaux-de-Fonds
Phone: +41 32 729 35 50
Fax: +41 32 729 35 60
Homepage: http://www.glenmarkpharma.com
Switzerland and South Korea may be separated by thousands of kilometres, but their economic relationship has never been closer. Bilateral trade reached nearly USD 8 billion in 2025, pharmaceutical flows…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
Natural remedies are on the rise. The USD 80 billion global natural health products market is projected to nearly double by 2033, according to Market Growth Reports, as patients with…
Ophthalmology is one of the hottest niches in pharma right now. Investment is flowing in, M&A is up, and a broad cast of actors – from Big Pharma to legacy…
One in six infections worldwide is now resistant to first-line antibiotics, making antimicrobial resistance (AMR) a major global health threat. Despite an extremely challenging commercial landscape, a handful of bold…
Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation. …
As global trade tensions escalate, Switzerland’s export-driven pharmaceutical industry finds itself at a challenging moment. In May 2025, the United States imposed tariffs of up to 39 percent on Swiss…
In an uncertain world, Europe – with Switzerland at its heart – is reclaiming its role as an epicentre for testing, scaling, and integrating new medical technologies. While much…
Manufacturing – long sidelined as a relatively prosaic element of the global pharma supply chain – is back in the news. Investment in manufacturing facilities is skyrocketing as sponsors rush…
Switzerland stands among the world’s leading pharmaceutical manufacturing and export hubs; though that position now faces headwinds from recent US policy moves, as detailed elsewhere in this report. Yet making…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals –…
For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact…
See our Cookie Privacy Policy Here
